profit from every $100 of sales.
$0$100
Vaxcyte
$63.37-2.04% today
+39.1% in 1 year
1-year low $43.061-year high $73.82
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Vaxcyte sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$767 million of profit last year.
SalesProfit
Vaxcyte vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Vaxcyte | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Vaxcyte's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -209 | -393 | -570 | -924 | |
| -214 | -383 | -554 | -899 | |
| -223 | -402 | -464 | -767 | |
| -3.44 | -4.14 | -3.80 | -5.63 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,006 | 1,408 | 3,511 | 3,003 |
| Cash | 835 | 397 | 388 | 174 |
| Total debt | 18 | 29 | 71 | 117 |
| Total liabilities | 53 | 167 | 205 | 317 |
| 954 | 1,240 | 3,306 | 2,686 | |
| 65 | 97 | 122 | 136 | |
| -18.2% | -24.5% | -13.3% | -26.0% | |
| -23.4% | -32.4% | -14.0% | -28.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -171 | -297 | -453 | -656 | |
| 6 | 68 | 119 | 57 | |
| -176 | -365 | -572 | -713 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 24 | 49 | 85 | 139 |
Valuation
- –
- –
- –
- 2.4×
- –
- –
- –
- -6.7%
- -7.6%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -35.0%
- -25.6%
- -32.5%
- -28.3%
- -35.0%
- –
Growth
- –
- –
- −40.9%
- –
- +27.2%
Financial health
- 0.2×
- 0.04
- 3.5%
- –
- 7.49
- 7.49
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 12%of 952
Bottom 20%of 884
Bottom 14%of 987
What analysts expect
- Average price target
- $83.00
- Range
- $77.00 – $89.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -2.30 | -1.77 | −29.7% |
| Feb 24, 2026 | -1.80 | -1.53 | −17.7% |
| Nov 4, 2025 | -1.56 | -1.27 | −22.8% |
| Aug 6, 2025 | -1.22 | -1.12 | −8.9% |
| May 7, 2025 | -1.04 | -1.02 | −2.0% |
| Feb 25, 2025 | -1.02 | -1.16 | +12.1% |
| Nov 5, 2024 | -0.83 | -1.10 | +24.5% |
| Aug 6, 2024 | -1.10 | -0.98 | −12.8% |
News
Vaxcyte narrows timing for pivotal VAX-31 data to late OctoberSeeking Alpha · Sep 6, 2026The newest story we have is from Sep 6, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
47No pass
Philip Fisher
33No pass
Peter Lynch
59No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
27No pass
Questions about Vaxcyte
Is Vaxcyte a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Vaxcyte AI analysis
What does Vaxcyte do?
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. It is in Biotechnology, based in San Carlos, CA, United States, with 507 employees.
Does Vaxcyte pay a dividend?
No. Vaxcyte does not pay a dividend at the moment.
Is Vaxcyte stock halal?
Yes. Vaxcyte passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Vaxcyte stock done over the past year?
Up 39.1% over the past twelve months, to $63.37. It traded between $43.06 and $73.82 and is 14.2% below its high.
Who are Vaxcyte's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Vaxcyte's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.